1. Medtech Insight
  2. >>Policy & Regulation

Flat-Lining US FDA: Failure To Invest May Have Consequences

 
• By Michael McCaughan

Old habits die hard when it comes to funding the FDA. When the agency is doing things well, it doesn’t get the money it needs to keep up the momentum. 

Blue electrocardiogram rhythm against black background
Appropriators' short-term savings goals could sacrifice long-term gains at the FDA. • Source: Shutterstock

The US Food and Drug Administration is set for another year of flat-line budgeting.

Key Takeaways

  • The FDA is facing a budget cut at a time when most of its activities are going well.

The legislative work on the agency’s fiscal year 2025 appropriations formally kicked off 11 June with a House Republican bill...

More from Legislation

More from Policy & Regulation